PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). gimeracil 85-115 cadherin 3 Homo sapiens 117-121 16897967-9 2006 S-1 is an oral anticancer agent in capsule, in which the following 2 modulators for 5-FU are combined to FT: one is CDHP(5-chloro-2,4-dihydroxypyridine) which increases blood concentrations and enhances pharmacological actions of 5-FU by potently inhibiting the degradation of 5-FU; and another is Oxo(potassium oxonate) which is localized in the mucosa of the gastrointestinal (GI) tract after oral administration and reduces GI toxicities provoked by 5-FU. gimeracil 121-151 cadherin 3 Homo sapiens 116-120 25169655-8 2015 The DPD inhibitor, 5-chloro-2, 4-dihydroxypyridine (CDHP) significantly enhanced 5-FU-induced apoptosis of CD44(high)/ESA(low) cells. gimeracil 19-50 cadherin 3 Homo sapiens 52-56 21378348-1 2011 UNLABELLED: The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone. gimeracil 71-80 cadherin 3 Homo sapiens 82-86 21378348-1 2011 UNLABELLED: The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone. gimeracil 71-80 cadherin 3 Homo sapiens 299-303 19822965-1 2009 We developed a rapid, simple and sensitive LC/MS/MS method for the simultaneous quantitation of tegafur (FT) and gimeracil (CDHP) in human plasma with a concentration range of 20-5000 and 2-500 ng/mL, respectively. gimeracil 113-122 cadherin 3 Homo sapiens 124-128